A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)
A Study with the drug Vericiguat for Patients with Heart Failure
Sponsor: Merck Sharp & Dohme Corp
Enrolling: Male and Female Patients
IRB Number: AAAR0118
U.S. Govt. ID: NCT01065454
Contact: Andrea Kim: 212-305-1368 / caccresearch@cumc.columbia.edu
Additional Study Information: This trial is looking to enroll patients with heart failure in order to study the effect and safety of the study drug, vericiguat, when compared to a placebo. Patients will remain on their regular standard of care treatment and will receive either a placebo or Vericiguat. All patients will be monitored closely by the study team.
This study is closed
Investigator
Maryjane Farr, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you awaiting heart transplantation? Yes No
Do you require continous home oxygen for lung disease? Yes No
Do you currently take sildenafil? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Andrea Kim
caccresearch@cumc.columbia.edu
212-305-1368
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE